RVB-001

N/A

Report date: 2024/12/04 16:35:37

Base Information

Drug NameRVB-001
Drug Alias NameRVB-001
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionSerine protease inhibitor Kazal-type 5 modulators
TargetsSerine protease inhibitor Kazal-type 5
Therapy Area/IndicationsNetherton Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesResVita Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesResVita Bio Inc
Inactive CompaniesN/A
Active IndicationsNetherton Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A